Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biotechnology Index NYSE ETF (FBT)

Biotechnology Index NYSE ETF (FBT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family First Trust Portfolios
  • Assets Under Management 2,182,477,000
  • Shares Outstanding, K 12,100
  • 60-Month Beta 1.14
Trade FBT with:
  • Price/Earnings ttm 25.68
  • Annual Dividend & Yield 0.00
  • Most Recent Dividend 0.020
  • Management Fee 0.55%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.82 +11.09%
on 01/04/21
184.21 unch
on 01/25/21
+10.34 (+5.95%)
since 12/24/20
3-Month
150.33 +22.54%
on 10/30/20
184.21 unch
on 01/25/21
+26.59 (+16.87%)
since 10/23/20
52-Week
108.08 +70.44%
on 03/18/20
184.21 unch
on 01/25/21
+38.74 (+26.63%)
since 01/24/20

Most Recent Stories

More News
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

PFE : 37.28 (+2.00%)
MRNA : 147.00 (+12.20%)
LLY : 212.35 (+3.01%)
IBB : 167.75 (+1.86%)
CNCR : 34.73 (+0.90%)
XBI : 157.14 (+3.00%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
SBIO : 57.54 (+2.82%)
PBE : 77.10 (+0.97%)
BTEC : 65.12 (+0.72%)
ARKG : 110.69 (+0.14%)
BNTX : 110.61 (+2.00%)
ETF Market Outlook & Picks for 2021

Two ETF experts share their market outlook and top picks for 2021.

XLI : 87.91 (-0.68%)
ICLN : 32.48 (-1.28%)
FBT : 184.21 (+2.01%)
EES : 42.49 (-0.05%)
KBWB : 52.89 (-0.97%)
RYH : 272.09 (+0.18%)
ARKG : 110.69 (+0.14%)
ONLN : 85.49 (-0.44%)
QQQM : 134.63 (+0.64%)
EDOC : 21.89 (+1.02%)
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

ALXN : 161.32 (+1.00%)
AZN : 54.01 (+1.43%)
PPH : 71.06 (+0.57%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
PJP : 78.66 (+1.86%)
PBE : 77.10 (+0.97%)
ETF Sectors to Bet on Positive Vaccine News

The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.

XLE : 41.64 (-1.02%)
IBB : 167.75 (+1.86%)
CARZ : 57.74 (-0.29%)
XES : 49.36 (-3.27%)
XBI : 157.14 (+3.00%)
FBT : 184.21 (+2.01%)
JETS : 21.70 (-2.47%)
PEJ : 43.16 (+0.68%)
KBWB : 52.89 (-0.97%)
KRE : 57.49 (-0.81%)
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

IBB : 167.75 (+1.86%)
XBI : 157.14 (+3.00%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
ARKG : 110.69 (+0.14%)
How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.

IBB : 167.75 (+1.86%)
XBI : 157.14 (+3.00%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
ARKG : 110.69 (+0.14%)
Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

AZN : 54.01 (+1.43%)
IBB : 167.75 (+1.86%)
XBI : 157.14 (+3.00%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
ARKG : 110.69 (+0.14%)
Red Hot ETF Areas Amid the Coronavirus Crisis

Let's check out some ETF areas that will remain solid investment picks even as the coronavirus cases show a sharp spike.

IBB : 167.75 (+1.86%)
XBI : 157.14 (+3.00%)
PNQI : 241.71 (+0.05%)
FBT : 184.21 (+2.01%)
ARKW : 166.17 (+0.83%)
FDN : 223.62 (+0.16%)
ESGU : 88.76 (+0.36%)
ESGV : 72.47 (+0.24%)
OGIG : 59.22 (+0.32%)
USSG : 34.97 (+0.23%)
How Are Biotech ETFs Reacting to Coronavirus Treatment News?

Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.

GILD : 68.16 (+1.82%)
LLY : 212.35 (+3.01%)
IBB : 167.75 (+1.86%)
XBI : 157.14 (+3.00%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
ARKG : 110.69 (+0.14%)
Biotech ETFs Soaring on COVID-19 Vaccine Progress

Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.

JNJ : 165.98 (+1.49%)
AZN : 54.01 (+1.43%)
MRNA : 147.00 (+12.20%)
NVAX : 131.46 (+3.53%)
IBB : 167.75 (+1.86%)
XBI : 157.14 (+3.00%)
BBH : 190.21 (+1.57%)
FBT : 184.21 (+2.01%)
ARKG : 110.69 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Fund Summary

The First Trust NYSE Arca Biotechnology Index Fund is and exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. The NYSE Arca Biotechnology Index is an equal dollar weighted...

See More

Top 10 Holdings

Name % Holdings
ILLUMINA INC 10,000.00%
Sarepta Therapeutics Inc 10,000.00%
Neurocrine Biosciences Inc 10,000.00%
Vertex Pharmaceuticals Inc 10,000.00%
GILEAD SCI 10,000.00%
BioMarin Pharmaceutical Inc 10,000.00%
Agios Pharmaceuticals 10,000.00%
INCYTE CORP 10,000.00%
FibroGen Inc. 10,000.00%
Regeneron Pharmaceuticals Inc 10,000.00%

See More

Key Turning Points

3rd Resistance Point 189.16
2nd Resistance Point 186.68
1st Resistance Point 185.45
Last Price 184.21
1st Support Level 181.74
2nd Support Level 179.26
3rd Support Level 178.03

See More

52-Week High 184.21
Last Price 184.21
Fibonacci 61.8% 155.13
Fibonacci 50% 146.15
Fibonacci 38.2% 137.16
52-Week Low 108.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar